second
two
invit
articl
review
develop
nucleosid
analogu
antivir
drug
written
target
audienc
virologist
nonchemist
well
chemist
may
familiar
field
first
paper
rather
provid
chronolog
account
chosen
examin
particular
exampl
structur
modif
made
nucleosid
analogu
proven
fruit
variou
antivir
anticanc
therapeut
first
review
cover
common
case
singl
modif
sugar
base
moieti
nucleosid
scaffold
paper
focus
recent
develop
especi
nucleosid
analogu
contain
one
modif
nucleosid
scaffold
hope
two
articl
provid
inform
histor
perspect
success
design
analogu
well
mani
candid
compound
encount
obstacl
second
two
invit
articl
review
develop
nucleosid
analogu
antivir
drug
written
target
audienc
virologist
nonchemist
well
chemist
may
familiar
field
first
paper
rather
provid
chronolog
account
chosen
examin
particular
exampl
structur
modif
made
nucleosid
analogu
proven
fruit
variou
antivir
anticanc
therapeut
first
review
cover
common
case
singl
modif
base
sugar
moieti
nucleosid
scaffold
second
paper
focus
recent
develop
field
especi
nucleosid
analogu
contain
one
modif
nucleosid
scaffold
term
nucleosid
first
use
leven
jacob
nucleosid
compos
sugar
moieti
nucleobas
wherea
nucleotid
compos
sugar
nucleobas
least
one
phosphat
phosphatelik
group
fig
nucleosid
nucleotid
play
import
role
replic
transcript
genet
inform
util
decad
chemotherapi
antiparasit
antibacteri
antivir
therapeut
de
clercq
perigaud
et
al
de
clercq
li
de
clercq
field
de
clercq
ideal
nucleosidetid
analogu
would
mimic
structur
natur
nucleosid
enough
recogn
cellular
viral
enzym
incorpor
dna
rna
replic
cycl
howev
analogu
would
possess
one
modif
would
lead
disrupt
andor
termin
replic
de
clercq
neyt
de
clercq
year
numer
modif
nucleo
ide
scaffold
made
includ
alter
sugar
nucleobas
glycosid
bond
phosphat
group
fig
describ
first
paper
modif
rang
ad
substitu
group
heterocycl
base
sugar
replac
atom
either
moieti
move
atom
differ
posit
combin
approach
perigaud
et
al
jordheim
et
al
recent
research
employ
latter
util
combin
mani
differ
type
modif
led
develop
wide
array
potent
nucleosid
therapeut
complex
structur
conveni
review
organ
base
modif
variou
posit
sugar
moieti
howev
mani
nucleosid
analogu
discuss
also
contain
modif
nucleobas
moieti
well
sugar
modif
explor
first
review
featur
nucleosid
combin
modif
carbocycl
nucleosid
altern
ring
size
acycl
nucleosid
acycl
nucleosid
phosphon
recent
modif
sugar
combin
http
receiv
octob
receiv
revis
form
novemb
accept
novemb
structureact
relationship
sar
studi
common
drug
design
typic
involv
walk
around
nucleosid
scaffold
make
particular
chang
observ
subsequ
effect
biolog
activ
one
studi
siddiqi
et
al
found
move
methyl
substitu
differ
posit
sugar
adenosin
nucleosid
yield
profound
differ
activ
siddiqi
et
al
exampl
replac
methyl
group
adenosin
analogu
led
larg
decreas
activ
adenosin
receptor
wherea
replac
methyl
group
increas
activ
siddiqi
et
al
analysi
cappellacci
et
al
found
replac
methyl
group
differ
effect
differ
adenosin
receptor
notabl
howev
overal
analogu
demonstr
littl
activ
fig
cappellacci
et
al
earli
nucleosid
analogu
includ
analogu
origin
synthes
damont
et
al
fig
damont
et
al
analogu
util
electrophil
fluorin
exocycl
doubl
bond
carbon
order
instal
fluoromethyl
group
posit
damont
et
al
unfortun
like
analogu
analogu
also
demonstr
antivir
activ
bovin
viral
diarrhea
viru
bvdv
hepat
c
viru
hcv
subgenom
replicon
assay
howev
notabl
analogu
toxic
damont
et
al
due
lack
antivir
activ
pursu
research
led
scientist
believ
lack
activ
demonstr
earli
due
instabl
glycosid
bond
addit
group
cappellacci
et
al
cho
et
al
gener
glycosid
bond
stabl
physiolog
condit
howev
cleavag
bond
occur
depend
variou
factor
includ
ph
type
nucleobas
temburnikar
seleyradtk
rio
et
al
lindahl
levi
miller
sinc
glycosid
bond
cleavag
occur
either
nucleophil
attack
carbon
sugar
stabil
leav
group
chang
substitu
hydrogen
group
posit
could
profound
effect
glycosid
bond
cleavag
either
steric
electron
effect
temburnikar
seleyradtk
berti
mccann
lenz
et
al
scientist
reason
howev
replac
hemiamin
oecen
glycosid
bond
oecec
bond
found
cnucleosid
would
abl
add
substitu
without
compromis
integr
glycosid
bond
temburnikar
seleyradtk
de
clercq
et
al
siegel
et
al
subsequ
led
develop
number
cnucleosid
analogu
regard
promis
cnucleosid
pursu
recent
cnucleosid
develop
gilead
fig
siegel
et
al
lo
et
al
sheahan
et
al
warren
et
al
metobo
et
al
sar
studi
focus
variou
analogu
found
analogu
display
broader
spectrum
antivir
activ
virus
hcv
yellow
fever
viru
yfv
viru
influenza
parainfluenza
ebola
viru
ebov
sever
acut
respiratori
syndrom
coronaviru
sarscov
best
antivir
activ
ebov
hmvec
cell
ec
siegel
et
al
find
especi
interest
sinc
analogu
show
reduc
potenc
much
narrow
spectrum
antivir
activ
instanc
higher
toxic
compar
analogu
siegel
et
al
contrast
analogu
demonstr
antivir
activ
due
surpris
broadspectrum
antivir
activ
found
analogu
research
gilead
perform
comput
dock
studi
triphosph
analogu
analogu
variou
rna
viru
polymeras
found
group
occupi
uniqu
pocket
present
viral
polymeras
bind
site
lead
increas
select
analogu
viral
polymeras
human
polymeras
warren
et
al
moreov
order
increas
deliveri
analogu
also
employ
mcguigan
protid
prodrug
nucleotid
approach
pertusati
et
al
mcguigan
et
al
mcguigan
et
al
mehel
et
al
mehel
et
al
mehel
protid
approach
proven
extrem
valuabl
deliveri
nucleotid
analogu
well
overcom
ratelimit
first
phosphoryl
step
dnarna
replic
nucleosid
nucleosid
analogu
phosphoryl
variou
host
cell
viral
kinas
triphosph
form
recogn
dna
polymeras
rna
polymeras
revers
transcriptas
incorpor
grow
chain
de
clercq
neyt
deval
sinc
triphosph
administ
directli
due
highli
charg
natur
phosphat
group
prodrug
help
deliv
nucleotid
cell
second
limit
associ
nucleosid
drug
first
phosphoryl
step
often
highli
specif
ratelimit
thu
nucleosid
analogu
often
recogn
appear
inact
mcguigan
et
al
mcguigan
et
al
mehel
et
al
herdewijn
et
al
balzarini
et
al
balzarini
et
al
overcom
obstacl
mcguigan
et
al
creat
protid
would
effici
deliv
monophosph
nucleosid
analogu
target
cell
bypass
ratelimit
first
phosphoryl
step
mcguigan
et
al
mcguigan
et
al
mcguigan
et
al
mehel
et
al
mehel
et
al
mehel
protid
util
uniqu
structur
three
tunabl
posit
aryl
amino
acid
ester
group
fig
mcguigan
et
al
mcguigan
et
al
mehel
et
al
aryl
group
amino
acid
ester
mask
neg
charg
monophosph
allow
protid
effici
cross
cell
membran
mcguigan
et
al
mehel
et
al
mehel
et
al
mehel
follow
metabol
variou
host
enzym
monophosph
nucleotid
analogu
success
deliv
subsequ
phosphoryl
activ
triphosph
mehel
et
al
mehel
et
al
mehel
use
mcguigan
protid
approach
compound
produc
remdesivir
increas
overal
antiebov
activ
ec
compar
parent
addit
also
increas
spectrum
antivir
activ
includ
virus
parent
nucleosid
activ
includ
west
nile
viru
wnv
lassa
fever
viru
middl
east
respiratori
syndrom
coronaviru
merscov
fig
sheahan
et
al
warren
et
al
studi
found
effect
postexposur
therapeut
ebovinfect
rhesu
monkey
mgkg
warren
et
al
studi
healthi
human
volunt
current
underway
order
evalu
pharmacokinet
clinic
safeti
specif
male
ebola
survivor
ebov
persist
semen
first
review
focus
modif
includ
arabinos
ara
analogu
configur
invert
well
monoand
difluoro
substitut
nucleosid
analogu
due
role
develop
first
medic
relev
nucleosid
analogu
greatli
impact
field
drug
design
second
articl
focu
recent
well
analogu
contain
addit
modif
especi
nucleobas
scaffold
numer
modifi
nucleosid
analogu
develop
promis
analogu
particularli
exhibit
activ
hcv
zhang
et
al
carrol
et
al
presenc
group
alter
configur
sugar
prevent
bind
subsequ
nucleotid
enzym
activ
site
thu
analogu
consid
nonoblig
chain
termin
adenosin
guanosin
cytidin
initi
pursu
display
micromolar
level
activ
hcv
wholecel
replicon
assay
fig
zhang
et
al
carrol
et
al
eldrup
et
al
eldrup
et
al
pierra
et
al
adenosin
analogu
prove
potent
ec
compar
guanosin
analogu
cytidin
analogu
eldrup
et
al
eldrup
et
al
pierra
et
al
interestingli
none
compound
demonstr
cytotox
vitro
eldrup
et
al
eldrup
et
al
pierra
et
al
unfortun
display
low
bioavail
well
high
rate
deamin
nucleobas
adenosin
analogu
increas
glycosid
bond
cleavag
purin
nucleosid
pyrophosphorylas
eldrup
et
al
eldrup
et
al
guanosin
analogu
also
exhibit
low
bioavail
due
insuffici
phosphoryl
decreas
cellular
uptak
eldrup
et
al
eldrup
et
al
mcguigan
et
al
mcguigan
et
al
initi
studi
disappoint
provid
research
start
point
develop
next
gener
hcv
nucleosid
therapeut
initi
studi
adenosin
guanosin
research
determin
bioavail
analogu
could
potenti
increas
remov
purin
ring
system
yield
deaza
analogu
deazapurin
nucleosid
natur
found
secondari
metabolit
produc
streptomyc
bacteria
due
strong
resembl
natur
purin
nucleosid
deazapurin
shown
disrupt
variou
biolog
function
therebi
lead
potent
therapeut
mccarti
bandarian
initi
deazamethyl
purin
synthes
promis
adenosin
fig
demonstr
broadspectrum
activ
numer
flavivirus
includ
hcv
denv
zika
viru
zikv
tickborn
enceph
tbev
yfv
ec
valu
rang
zmurko
et
al
olsen
et
al
schul
et
al
eyer
et
al
eyer
et
al
eyer
et
al
di
francesco
et
al
analysi
found
analogu
associ
cellular
toxic
h
cell
hcv
rna
replic
inhibit
subgenom
replicon
assay
olsen
et
al
di
francesco
et
al
carrol
et
al
comparison
parent
analogu
adenosin
demonstr
dramat
increas
halflif
oral
bioavail
sinc
longer
suscept
deamin
cleavag
adenosinemetabol
enzym
olsen
et
al
bloch
et
al
unfortun
approach
prove
ineffect
correspond
guanosin
analogu
viral
strain
mutat
introduc
thu
adenosin
analogu
origin
pursu
olsen
et
al
di
francesco
et
al
subsequ
howev
research
found
addit
prodrug
moieti
aforement
mcguigan
protid
greatli
enhanc
antivir
activ
guanosin
sizun
et
al
one
success
analogu
fig
prodrug
origin
develop
idenix
util
tbusat
moieti
function
nbenzylphosphoramid
group
ho
tbusat
nbenzylphosphoramid
impart
signific
increas
antihcv
activ
compar
parent
compound
sizun
et
al
crettonscott
et
al
sar
studi
sizun
et
al
found
ho
tbusat
nbenzylphosphoramid
deriv
potent
analogu
ec
associ
cytotox
hcv
subgenom
luciferas
replicon
system
sizun
et
al
crettonscott
et
al
analysi
reveal
well
toler
chimpanze
model
thu
research
turn
test
human
patient
phase
ii
clinic
trial
determin
effect
patient
chronic
hcv
infect
thu
support
studi
clinic
applic
sizun
et
al
zhou
et
al
lalezari
et
al
relat
studi
mcguigan
et
al
found
addit
protid
moieti
result
increas
activ
hcv
huh
cell
well
lack
cytotox
investig
mcguigan
led
develop
util
phosphoramid
protid
moieti
naphthyl
group
aromat
compon
lalanin
amino
acid
compon
tbuch
group
aliphat
compon
fig
mcguigan
et
al
mcguigan
et
al
analogu
consid
doubl
prodrug
sinc
carbonyl
group
posit
guanin
base
replac
methoxi
group
follow
hydrolysi
revert
carbonyl
mcguigan
et
al
modif
prove
essenti
consist
improv
activ
hcv
replicon
across
protid
deriv
compar
parent
mcguigan
et
al
analysi
reveal
potent
analogu
ec
valu
cc
valu
mehel
mcguigan
et
al
importantli
approach
deliv
substanti
higher
level
compar
parent
analogu
increas
halflif
h
mcguigan
et
al
vernachio
et
al
similarli
studi
found
combin
therapi
ribavirin
result
signific
synergist
antidenv
activ
vitro
synergi
score
yeo
et
al
promis
result
prompt
clinic
analysi
includ
phase
iii
trial
anoth
antihcv
experiment
drug
daclatasvir
vernachio
et
al
unfortun
sever
cardiotox
complic
soon
discov
thu
withdrawn
clinic
studi
baumgart
et
al
feng
et
al
gentil
et
al
similar
toxic
reason
due
fact
share
parent
analogu
also
pull
clinic
trial
gentil
et
al
luo
et
al
mention
first
review
research
capit
uniqu
properti
fluorin
impart
nucleosid
analogu
decad
liu
et
al
pankiewicz
watanab
pankiewicz
fluorin
often
use
isoster
replac
sinc
similar
size
hydrogen
also
similar
electroneg
hydroxyl
group
found
nucleosid
liu
et
al
presenc
fluorin
sugar
ring
greatli
influenc
conform
sugar
pucker
ring
system
turn
effect
overal
conform
entir
nucleosid
well
recognit
differ
enzym
saenger
cantor
ikeda
et
al
wojtowiczrajchel
furthermor
studi
demonstr
presenc
fluorin
sugar
greatli
decreas
nucleosid
suscept
enzymat
cleavag
glycosid
bond
liu
et
al
wojtowiczrajchel
bohm
et
al
kirk
park
et
al
gudmundsson
et
al
one
earli
success
analogu
demonstr
potent
hcv
inhibit
ec
cytotox
stuyver
et
al
unfortun
target
hcv
nonstructur
polymeras
also
shown
target
cellular
polymeras
thu
pursu
stuyver
et
al
brox
et
al
richardson
et
al
due
success
analogu
well
known
impact
use
fluorin
nucleosid
drug
design
clark
et
al
sought
combin
two
modif
yield
analogu
fig
clark
et
al
hope
combin
substitu
novel
analogu
would
demonstr
potent
antivir
activ
addit
group
would
target
analogu
viral
polymeras
rather
human
polymeras
thu
result
lower
cytotox
compar
analogu
hcv
replicon
assay
cytidin
analogu
demonstr
ec
associ
cytotox
uridin
analogu
inact
although
also
cytotox
clark
et
al
mention
previous
one
limit
nucleosid
analogu
first
phosphoryl
step
viral
cellular
kinas
interestingli
analogu
demonstr
antivir
activ
hcv
replicon
assay
triphosph
analogu
demonstr
potent
inhibitori
activ
hcv
ic
murakami
et
al
suggest
analogu
effici
phosphoryl
monophosph
thu
use
phosphoramid
protid
method
could
potenti
increas
antivir
activ
extens
sar
studi
sofia
et
al
found
phosphoramid
structur
isopropyl
alkyl
chain
lalanin
phenyl
aromat
substitu
fig
greatli
increas
antivir
activ
uridin
analogu
ec
lam
et
al
analysi
determin
safeti
found
analogu
demonstr
cytotox
numer
cell
line
includ
human
hepatocyt
cell
line
human
pancreat
cell
line
human
tlymphoblast
cell
line
cem
mixtur
diastereom
phosphoru
center
import
determin
isom
demonstr
greater
antivir
activ
potenti
toxic
whether
two
isom
work
synergist
sofia
et
al
found
sp
isom
sofosbuvir
inde
activ
ec
rp
isom
ec
neither
analogu
demonstr
cytotox
concentr
importantli
sofosbuvir
consist
produc
high
level
triphosph
liver
cell
across
speci
test
lam
et
al
murakami
et
al
promis
result
led
develop
sofosbuvir
clinic
trial
ultim
sofosbuvir
approv
fda
name
sovaldi
moreov
sofosbuvir
also
approv
combin
drug
ribavirin
ledipasvir
use
prophylaxi
liver
transplant
treatment
recur
hcv
infect
well
numer
hcv
genotyp
charlton
et
al
curri
et
al
desnoy
et
al
foster
et
al
gane
et
al
gane
et
al
jacobson
et
al
lawitz
et
al
field
nucleosid
analogu
drug
design
greatli
benefit
combin
approach
wherebi
research
merg
differ
structur
modif
prove
essenti
antivir
activ
one
analogu
highlight
combin
modif
deaza
purin
nucleobas
substitut
carbon
creat
cnucleosid
mcguigan
protid
technolog
lo
et
al
sheahan
et
al
anoth
analogu
use
strategi
fig
cnucleosid
adenosin
analogu
origin
develop
research
gilead
scienc
hcv
treatment
mention
previous
group
occupi
pocket
viral
polymeras
bind
site
lead
increas
select
analogu
viral
human
polymeras
warren
et
al
like
employ
cnucleosid
replac
hemiamin
oecen
glycosid
bond
oecec
bond
thu
decreas
nucleosid
analogu
suscept
enzymat
glycosid
bond
cleavag
temburnikar
seleyradtk
de
clercq
et
al
siegel
et
al
also
observ
studi
analogu
exhibit
increas
antivir
activ
halflif
oral
bioavail
sinc
analogu
longer
suscept
deamin
cleavag
adenosinemetabol
enzym
zmurko
et
al
olsen
et
al
di
francesco
et
al
bloch
et
al
previous
mention
addit
group
also
prove
fruit
sinc
incorpor
grow
strand
analogu
modif
prevent
incom
nucleosid
triphosph
bind
activ
site
hcv
thu
act
nonoblig
chain
termin
migliaccio
et
al
modif
mind
cho
et
al
synthes
novel
adenosin
analogu
fig
screen
activ
hcv
unfortun
analogu
fail
display
antivir
activ
wholecel
replicon
assay
subsequ
shown
due
presenc
group
limit
first
phosphoryl
step
like
due
chang
sugar
pucker
affect
recognit
kinas
enzym
surprisingli
howev
correspond
triphosph
display
ic
valu
thu
protid
approach
employ
overcom
ratelimit
phosphoryl
step
well
increas
amount
triphosph
deliv
target
cell
prove
success
found
phosphoramid
prodrug
fig
demonstr
moder
hcv
activ
replicon
assay
ec
effici
convert
activ
triphosph
subsequ
pharmacokinet
studi
determin
triphosph
level
hamster
liver
reveal
phosphoramid
analogu
yield
adequ
amount
triphosph
follow
oral
absorpt
order
overcom
limit
cho
et
al
util
doubl
prodrug
approach
protect
use
isobutyr
group
fig
modif
increas
lipophil
oral
absorpt
also
result
much
higher
level
triphosph
primari
human
hepatocyt
similar
sofosbuvir
doubleprodrug
analogu
diastereomer
mixtur
thu
analysi
found
sp
isom
potent
hcv
replicon
assay
deliv
higher
level
triphosph
primari
human
hepatocyt
compar
rp
isom
due
promis
antivir
profil
sp
isom
later
known
analogu
chosen
clinic
evalu
feng
et
al
murakami
et
al
confin
cyano
group
also
found
use
posit
nucleosid
sugar
moieti
mention
previous
first
nucleosid
discov
medicin
properti
arabinos
ara
analogu
arac
fig
demonstr
potent
activ
numer
cancer
includ
nonhodgkin
lymphoma
myeloid
leukemia
acut
myeloblast
leukemia
mani
other
rees
schiller
schilski
et
al
bodey
et
al
hiddemann
livingston
carter
unfortun
numer
drawback
use
arac
anticanc
treatment
includ
short
halflif
plasma
inactiv
deamin
inact
uracil
metabolit
cytidin
deaminas
develop
resist
ineffect
solid
tumor
chabner
et
al
princ
et
al
ho
plunkett
gandhi
later
shown
ad
variou
group
posit
could
profound
effect
stabil
analogu
decreas
suscept
cytidin
deaminas
studi
found
introduct
electronwithdraw
substitu
posit
increas
acid
proton
thu
could
occur
result
dna
strand
break
azuma
et
al
matsuda
et
al
matsuda
et
al
matsuda
azuma
particularli
interest
due
hypothesi
radiat
therapi
caus
dna
strand
break
lead
tumor
cell
death
baskar
et
al
thu
addit
group
employ
yield
cndac
fig
demonstr
potent
vitro
activ
numer
human
tumor
cell
sarcoma
osteosarcoma
fibroblastoma
carcinoma
azuma
et
al
azuma
et
al
azuma
et
al
matsuda
et
al
matsuda
azuma
tanaka
et
al
comparison
parent
analogu
arac
cndac
demonstr
potent
cytotox
tumor
cell
line
ic
valu
wherea
arac
activ
cell
line
ic
valu
matsuda
et
al
furthermor
cndac
effect
solid
tumor
wherea
arac
wide
use
activ
solid
tumor
matsuda
et
al
tanaka
et
al
led
seri
clinic
trial
includ
one
cndac
current
phase
iii
trial
acut
myeloid
leukemia
acut
lymphat
leukemia
kantarjian
et
al
kantarjian
et
al
kantarjian
et
al
anoth
prodrug
cndac
sapacitabin
fig
phase
iii
trial
acut
myeloid
leukemia
myelodysplast
syndrom
kantarjian
et
al
kantarjian
et
al
studi
group
research
found
acetylenederiv
analogu
import
sugar
modif
associ
potent
antivir
effect
furthermor
modif
posit
adenosin
analogu
remov
nitrogen
yield
analogu
addit
carbamoyl
moieti
led
profound
antivir
activ
denv
chen
et
al
chen
et
al
deng
et
al
analogu
demonstr
moder
antidenv
activ
ec
also
associ
cytotox
chen
et
al
interestingli
analogu
fig
demonstr
similar
potenc
without
associ
cytotox
yin
et
al
shang
et
al
lo
et
al
studi
found
analogu
cytotox
across
numer
cell
line
inhibit
ec
yin
et
al
importantli
also
effect
three
serotyp
yin
et
al
critic
patient
fig
structur
modifi
analogu
arac
cndac
prodrug
sapacitabin
fig
structur
adenosin
base
analogu
like
develop
sever
dengu
hemorrhag
fever
dengu
shock
syndrom
infect
second
time
differ
serotyp
thu
analogu
activ
serotyp
highli
sought
katzelnick
et
al
low
et
al
furthermor
studi
found
also
effect
flavivirus
includ
wnv
yfv
hcv
zikv
tbev
well
enteroviru
deng
et
al
deng
et
al
yin
et
al
shang
et
al
lo
et
al
qing
et
al
elucid
mechan
action
determin
triphosph
interact
flaviviru
rdrp
ic
serv
chain
termin
similar
fashion
analogu
therebi
halt
viral
rna
elong
deng
et
al
yin
et
al
vivo
studi
determin
could
suppress
peak
viremia
infect
mice
complet
protect
death
yin
et
al
studi
flavivirus
current
way
determin
could
prove
broadspectrum
therapeut
varieti
flavivirus
deng
et
al
lo
et
al
qing
et
al
earli
exampl
modif
posit
nucleosid
sugar
led
develop
novel
analogu
nucleosid
mikhailov
et
al
franchetti
et
al
cappellacci
et
al
howev
nucleosid
veal
et
al
horwitz
et
al
mitsuya
broder
nucleosid
hostetl
et
al
ultim
prove
promis
develop
analogu
cover
extens
previou
review
discuss
discoveri
natur
occur
nucleosid
analogu
thoma
et
al
modif
posit
furanos
ring
rather
uncommon
drug
design
mainli
due
synthet
challeng
facil
synthet
rout
develop
research
began
pursu
interest
analogu
research
soon
note
modif
posit
furanos
ring
chang
sugar
pucker
north
conform
common
natur
rna
nucleosid
kool
et
al
south
conform
waga
et
al
mention
previous
affect
recognit
differ
enzym
thu
signific
impact
biolog
activ
saenger
cantor
ikeda
et
al
mention
previous
fluorin
substitut
util
number
posit
nucleobas
sugar
moieti
howev
one
lesser
explor
posit
substitut
nucleosid
sugar
one
first
nucleosid
analogu
isol
streptomyc
calvu
thoma
et
al
nt
correct
structur
analogu
later
name
nucleocidin
elucid
fig
jenkin
et
al
jenkin
et
al
morton
et
al
owen
et
al
analogu
one
first
exampl
furanos
sugar
also
possess
novel
group
jenkin
et
al
jenkin
et
al
morton
et
al
owen
et
al
uniqu
structur
endow
nucleocidin
broad
antiparasit
spectrum
particularli
trypanosom
howev
practic
use
analogu
therapeut
sever
limit
due
toxic
thoma
et
al
hewitt
et
al
initi
discoveri
nucleocidin
prompt
research
pursu
modifi
nucleosid
analogu
effort
decreas
overal
toxic
one
exampl
develop
guillerm
et
al
potenti
sadenosyllhomocystein
hydrolas
sahas
inhibitor
fig
guillerm
et
al
base
mechan
action
sahas
hypothes
lack
would
complet
inhibit
catalysi
howev
test
sahas
determin
lower
affin
sahas
compar
natur
adenosin
thu
modif
prove
unsuccess
guillerm
et
al
anoth
analogu
relat
nucleocidin
fig
analogu
demonstr
similar
inhibit
growth
mous
leukemia
cell
parent
greater
activ
previous
report
prodrug
ajmera
et
al
sinc
group
analogu
convert
nucleotid
incorpor
polymeras
instead
presenc
group
make
glycosid
bond
unusu
acidlabil
increas
glycosid
bond
cleavag
uridin
phosphorylas
thu
deliv
increas
amount
tumor
site
ajmera
et
al
ajmera
et
al
comparison
anoth
prodrug
discuss
demonstr
ic
increas
glycosid
bond
hydrolysi
wherea
ic
fail
undergo
signific
hydrolysi
ajmera
et
al
analogu
appear
promis
potenti
anticanc
agent
studi
yet
report
anoth
common
isoster
modif
nucleosid
drug
design
substitut
methyl
group
hydrogen
modif
explor
cappellacci
et
al
zhang
et
al
carrol
et
al
migliaccio
et
al
eldrup
et
al
eldrup
et
al
pierra
et
al
mikhailov
et
al
franchetti
et
al
cappellacci
et
al
orlov
et
al
posit
furanos
ring
littl
research
report
presenc
methyl
group
posit
mention
previous
found
addit
alter
reactiv
group
compar
natur
nucleosid
due
steric
effect
waga
et
al
thu
modif
consid
interest
avenu
pursu
synthesi
analogu
pioneer
waga
et
al
earli
use
potenti
anticanc
andor
antivir
therapeut
waga
et
al
waga
et
al
chang
sugar
pucker
due
presenc
substitu
impart
analogu
interest
characterist
waga
et
al
also
hypothes
modif
could
act
synergist
sugar
modif
fig
waga
et
al
combin
modif
dideoxi
sugar
sugar
satur
dideoxi
sugar
variou
nucleobas
result
analogu
screen
cell
waga
et
al
analogu
fail
display
notabl
antivir
activ
ic
valu
rang
howev
analogu
analogu
display
potent
activ
ic
valu
respect
waga
et
al
nomura
et
al
thymidin
analogu
display
cytotox
cytidin
analogu
quit
toxic
cc
valu
thu
analogu
pursu
waga
et
al
nomura
et
al
year
later
modif
revisit
gosselin
et
al
synthes
ribos
seri
focus
nucleobas
modif
instead
sugar
modif
seen
studi
waga
et
al
fig
griffon
et
al
like
analogu
synthes
waga
ribos
analogu
evalu
inhibitori
effect
replic
cell
howev
none
demonstr
meaning
antivir
activ
griffon
et
al
analogu
also
test
activ
virus
includ
hbv
hbv
dnatransfect
cell
cell
yfv
bhk
cell
antivir
activ
cytotox
observ
analogu
either
viru
griffon
et
al
pursuit
modif
approach
abandon
earli
success
azt
zidovudin
hostetl
et
al
shirasaka
et
al
horwitz
et
al
bear
modif
research
sought
util
modif
differ
posit
sugar
ring
either
increas
antivir
activ
perhap
importantli
decreas
cellular
toxic
one
exampl
garner
earli
attent
addit
azid
group
sugar
due
result
electronwithdraw
effect
azid
group
sugar
pucker
maag
et
al
thu
seri
nucleosid
synthes
demonstr
potent
antihiv
activ
first
nucleosid
analogu
potent
antihiv
activ
azido
group
posit
posit
fig
maag
et
al
chen
et
al
interestingli
presenc
group
analogu
affect
group
way
brought
two
group
closer
proxim
maag
et
al
chen
et
al
due
electroneg
group
prefer
pseudoaxi
orient
forc
group
pseudoequatori
posit
caus
sugar
adopt
rnatyp
conform
maag
et
al
thu
analogu
retain
moieti
contrast
azt
hiv
chain
termin
chang
sugar
pucker
allow
analogu
still
act
dna
chain
termin
howev
design
pseudooblig
chain
termin
maag
et
al
chen
et
al
yamada
et
al
none
analogu
activ
azt
isol
demonstr
potent
activ
maag
et
al
chen
et
al
ic
analogu
associ
cytotox
wherea
analogu
possess
ic
valu
also
cytotox
maag
et
al
furthermor
analogu
demonstr
equipot
activ
ic
valu
compar
azt
cell
chen
et
al
even
signific
observ
effect
strain
aztresist
maag
et
al
chen
et
al
unfortun
analogu
prove
increas
cytotox
compar
azt
never
progress
clinic
contrast
one
success
analogu
later
term
demonstr
potent
antihcv
activ
fig
klumpp
et
al
analogu
origin
discov
sar
studi
roch
found
show
ic
hcv
replicon
prolifer
assay
triphosph
inhibit
hcv
ic
analysi
found
also
activ
mutant
strain
hcv
promis
result
along
low
cytotox
led
research
investig
virus
found
effect
hcv
denv
serotyp
ec
rang
primari
human
macrophag
nguyen
et
al
well
respiratori
syncyti
viru
rsv
ic
wang
et
al
recent
studi
found
micromolar
activ
henipavirus
nipah
hendra
unfortun
like
mani
nucleosid
analogu
suffer
low
bioavail
thu
triisobutyl
ester
prodrug
moieti
introduc
give
balapiravir
fig
klumpp
smith
robert
et
al
toniutto
et
al
brandl
et
al
although
balapiravir
demonstr
increas
antivir
activ
compar
parent
analogu
efficaci
clinic
trial
hcv
klumpp
smith
robert
et
al
robert
et
al
robson
et
al
pockro
et
al
develop
potent
nucleosid
analogu
sofosbuvir
well
advers
toxic
pockro
et
al
halt
advanc
analogu
hcv
therapeut
later
balapiravir
analyz
clinic
studi
denv
nguyen
et
al
chen
et
al
howev
treatment
well
toler
due
advers
effect
decreas
viral
load
fever
clearanc
time
thu
clinic
trial
termin
analogu
earli
interest
includ
nucleosid
fig
use
antihcv
analogu
eyer
et
al
klumpp
et
al
smith
et
al
rondla
et
al
nilsson
et
al
featur
group
ara
hydroxyl
group
discov
sar
studi
author
attempt
develop
potent
ribonucleosid
hcv
klumpp
et
al
interestingli
prove
potent
analogu
test
ic
associ
cytotox
klumpp
et
al
furthermor
studi
found
potent
antihcv
analogu
also
effect
tbev
ec
associ
cytotox
eyer
et
al
similarli
research
analyz
chang
antivir
activ
ara
hydroxyl
group
substitut
methyl
group
yield
analogu
fig
rondla
et
al
nilsson
et
al
unfortun
determin
analogu
demonstr
potent
antihcv
activ
howev
addit
phosphoramid
prodrug
moieti
greatli
increas
antivir
activ
ec
valu
rang
rondla
et
al
nilsson
et
al
increas
activ
led
research
pursu
phosphoramid
modif
order
increas
antihcv
activ
even
studi
current
way
due
initi
success
variou
analogu
scientist
sought
potent
candid
util
moieti
termin
nitrogen
atom
group
led
earli
develop
fig
demonstr
activ
hiv
ec
oyang
et
al
unfortun
studi
mous
model
demonstr
toxic
mgkg
dose
per
day
oyang
et
al
thu
studi
discontinu
initi
find
toxic
research
sought
addit
analogu
effort
retain
biolog
activ
decreas
cytotox
sar
studi
focus
differ
nomura
et
al
determin
analogu
fig
demonstr
activ
tumor
cell
herp
simplex
viru
hsv
potent
activ
ec
accompani
cytotox
nomura
et
al
interestingli
correspond
ribos
deriv
demonstr
similar
antivir
activ
fig
structur
triisobutyl
ester
prodrug
balapiravir
fig
novel
structur
exhibit
much
greater
level
cytotox
thu
deoxyribos
analogu
select
studi
synthesi
analogu
initi
challeng
sinc
sugar
exhibit
low
reactiv
glycosyl
reaction
thu
make
difficult
add
necessari
heterocycl
base
research
subsequ
develop
novel
synthet
approach
modifi
natur
occur
deoxyribonucleosid
start
materi
allow
readili
avail
analogu
nomura
et
al
kohgo
et
al
subsequ
studi
show
cdg
cada
analogu
fig
exhibit
subnanomolar
level
activ
ec
nm
ec
nm
respect
associ
signific
toxic
kohgo
et
al
comparison
cda
analogu
cdi
fig
exhibit
submicromolar
activ
ec
littl
cytotox
kohgo
et
al
cada
cdg
analyz
takamatsu
et
al
found
analogu
demonstr
potent
activ
also
potent
activ
hepat
b
viru
hbv
ec
nm
analogu
less
cytotox
previous
report
kohgo
et
al
takamatsu
et
al
discoveri
antihiv
activ
nucleosid
analogu
mani
scientist
believ
hiv
therapeut
lack
group
could
act
chain
termin
absenc
group
impart
potent
antihiv
effect
also
sever
disadvantag
includ
poor
phosphoryl
reduc
recognit
polymeras
kirbi
et
al
galloismontbrun
et
al
hattori
et
al
nakata
et
al
research
therefor
attempt
design
novel
analogu
would
retain
antivir
potenc
well
recognit
requir
activ
incorpor
one
analogu
efda
fig
notabl
efda
demonstr
potent
antihiv
activ
ec
nm
also
signific
activ
nucleosid
revers
transcriptas
inhibitor
nrti
resist
strain
kirbi
et
al
hattori
et
al
ohrui
ohrui
et
al
design
efda
scaffold
result
combin
sever
strateg
structur
modif
exampl
fluorin
moieti
adenosin
nucleobas
chosen
due
observ
fluorin
anoth
halogen
nucleosid
analogu
significantli
enhanc
antivir
activ
kirbi
et
al
kawamoto
et
al
increas
activ
due
decreas
suscept
efda
adenosin
deaminas
result
highli
electroneg
fluorin
kirbi
et
al
kawamoto
et
al
addit
moieti
also
play
role
decreas
deamin
efda
adenosin
deaminas
thu
two
modif
work
synergist
kirbi
et
al
second
modif
retent
ensur
recognit
kinas
also
known
import
relat
addit
group
lead
efda
strongli
favor
north
conform
number
studi
determin
revers
transcriptas
rt
prefer
nrti
andor
incom
nucleotid
north
confirm
thu
efda
bind
rt
optim
kirbi
et
al
kirbi
et
al
boyer
et
al
marquez
et
al
michailidi
et
al
furthermor
efda
readili
recogn
incorpor
rt
inhibit
human
dna
polymeras
mitochondri
dna
polymeras
thu
efda
display
superior
toxic
profil
compar
nrti
ohrui
ohrui
et
al
michailidi
et
al
sohl
et
al
addit
group
profound
effect
sugar
pucker
thu
increas
bind
affin
rt
moieti
also
endow
efda
two
uniqu
mechan
action
instead
oblig
nonoblig
delay
pseudooblig
chain
termin
typic
nucleosid
analogu
efda
act
translocationdefect
revers
transcriptas
inhibitor
tdrti
michailidi
et
al
muftuoglu
et
al
sali
et
al
efdatp
incorpor
rt
terminu
uniqu
structur
efda
block
transloc
primer
strand
viral
polymeras
thu
nucleotid
incorpor
michailidi
et
al
muftuoglu
et
al
sali
et
al
interestingli
efda
also
act
tradit
nonoblig
chain
termin
sinc
retain
michailidi
et
al
muftuoglu
et
al
sali
et
al
due
low
toxic
profil
highli
potent
antihiv
activ
efda
progress
clinic
trial
name
sponsor
merck
modif
variou
posit
furanos
ring
common
import
group
nucleotid
incorpor
dna
rna
synthesi
initi
caus
research
avoid
modif
instanc
howev
seen
truncat
carbocycl
nucleosid
relat
aristeromycin
neplanocin
develop
schneller
seley
borchardt
other
remov
replac
group
andor
group
prove
benefici
sinc
analogu
could
longer
phosphoryl
thu
toxic
observ
parent
analogu
aristeromycin
neplanocin
occur
truncat
analogu
da
schneller
barnard
et
al
hegd
et
al
hegd
et
al
seley
et
al
seley
et
al
seley
et
al
seley
et
al
hasob
et
al
research
also
util
approach
advantag
order
decreas
overal
toxic
variou
nucleosid
analogu
one
earli
nucleosid
analogu
incorpor
substitut
doxifluridin
fig
instead
group
methyl
posit
diasio
bollag
hartmann
cook
et
al
like
analogu
phosphoryl
convert
correspond
triphosph
instead
exert
effect
act
prodrug
releas
result
glycosid
bond
cleavag
human
phosphorylas
kono
et
al
sommadossi
et
al
analogu
demonstr
broad
rang
activ
numer
cancer
includ
colorect
leukemia
melanoma
diasio
cook
et
al
fig
uniqu
structur
sommadossi
et
al
ishitsuka
et
al
kramer
et
al
tevaearai
et
al
furthermor
compar
fluorin
pyrimidin
exhibit
higher
therapeut
index
less
immunosuppress
diasio
kramer
et
al
ohta
et
al
sinc
initi
discoveri
mid
progress
phase
numer
phase
ii
clinic
trial
treatment
squamou
cell
carcinoma
advanc
breast
cancer
advanc
colorect
adenocarcinoma
other
alberto
et
al
abel
et
al
abel
et
al
van
oosterom
et
al
despit
success
fda
yet
approv
anticanc
treatment
unit
state
thu
research
need
order
better
determin
potenti
side
effect
could
associ
analogu
final
section
dedic
describ
sever
type
nucleosid
analogu
util
novel
uniqu
structur
modif
well
explain
use
unconvent
way
first
articl
variou
expand
purin
nucleobas
describ
includ
nelson
leonard
benzylexpand
nucleosid
leonard
et
al
leonard
et
al
leonard
et
al
leonard
seleyradtk
thienoexpand
nucleosid
seleyradtk
et
al
wauchop
et
al
chen
et
al
chen
et
al
exampl
interest
tricycl
analogu
dualfac
base
janu
nucleosid
name
janu
roman
god
gate
door
fig
zhou
et
al
chung
et
al
uniqu
nucleosid
present
watsoncrick
donoracceptor
base
pair
two
differ
face
nucleobas
rotat
glycosid
bond
thu
form
stabl
base
pair
one
complementari
nucleosid
zhou
et
al
chung
et
al
synthesi
ribos
janustyp
nucleosid
met
challeng
howev
ribos
jau
jag
analogu
demonstr
moder
activ
hcv
ec
valu
respect
zhou
et
al
unfortun
demonstr
signific
toxic
numer
cell
line
zhou
et
al
thu
extens
pursu
serendipit
outcom
earli
studi
seleyradtk
thiopheneexpand
tricycl
analogu
led
new
class
novel
nucleosid
analogu
treat
tricycl
nucleosid
raney
nickel
sulfur
middl
ring
remov
leav
two
outer
ring
intact
therebi
result
flexibl
nucleosid
uniqu
analogu
term
flexim
fig
seley
et
al
featur
purin
ring
split
imidazol
pyrimidin
moieti
remain
connect
singl
carboncarbon
bond
imidazol
pyrimidin
proxim
flexim
imidazol
pyrimidin
distal
flexim
fig
seley
et
al
wauchop
et
al
design
retain
hydrogen
bond
pattern
necessari
nucleosiderecogn
enzym
creat
increas
flexibl
allow
altern
interact
enzym
bind
site
result
number
highli
benefici
properti
seley
et
al
seley
et
al
inher
flexibl
analogu
allow
free
rotat
carboncarbon
bond
increas
rotat
degre
freedom
allow
flexim
interact
altern
amino
acid
bind
pocket
previous
unattain
parent
nucleosid
seley
et
al
polak
et
al
seley
studi
found
introduct
flexibl
nucleosid
scaffold
correspond
increas
bind
affin
compar
correspond
rigid
inhibitor
well
abil
circumv
point
mutat
bind
site
thu
overcom
develop
drug
resist
seley
et
al
polak
et
al
seley
date
number
differ
type
flexim
thienophen
analogu
fdaapprov
nucleosid
analogu
synthes
seleyradtk
et
al
chen
et
al
seley
et
al
seley
et
al
zimmermann
et
al
zimmermann
et
al
howev
promis
analogu
recent
acycl
flexim
base
fdaapprov
drug
acyclovir
doubli
flexibl
nucleosid
demonstr
potent
micromolar
activ
numer
rna
virus
fig
yate
et
al
peter
et
al
potent
analogu
methoxyprodrug
flexacyclovir
ec
merscov
also
potent
activ
ebov
yate
et
al
peter
et
al
recent
studi
analogu
found
submicromolar
activ
denv
ec
yfv
ec
well
potent
inhibitori
activ
correspond
triphosph
denv
zikv
ic
respect
seleyradtk
importantli
analogu
demonstr
littl
cytotox
yate
et
al
peter
et
al
due
broadspectrum
antivir
activ
current
undergo
analysi
determin
mechan
action
detail
previou
review
nucleosid
analogu
remain
cornerston
antivir
anticanc
therapeut
particularli
combin
therapi
addit
structur
biolog
inform
becom
avail
new
complex
modif
continu
pursu
hope
two
articl
increas
reader
understand
histor
modif
nucleosid
scaffold
justif
modif
signific
modernday
therapeut
